Vyndamax

Chemical Nametafamidis
Dosage FormCapsule (oral; 61 mg)
Drug ClassInhibitors
SystemCardiovascular
CompanyPfizer
Approval Year2019

Indication

  • For the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization
Last updated on 4/23/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyndamax (tafamidis) Prescribing Information. 2019Pfizer Inc., New York, NY